Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308178 · ClinicalTrials.gov registry record · NA
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
A NA study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00308178: Completed NA study, sponsored by Harold J. Burstein, MD, PhD.
NCT00308178 is a NA study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308178, a NA study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor.
Interventions
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308178
The ClinicalTrials.gov registry entry for NCT00308178 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harold J. Burstein, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abraxane is the first listed.
NCT00308178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00308178 about?
NCT00308178 is a clinical study titled "Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer". The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a ...
What is the current status of trial NCT00308178?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2006-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00308178?
The interventions under investigation include: Abraxane (DRUG).
Who is sponsoring clinical trial NCT00308178?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.